Damora Therapeutics, Inc. Net Income Loss

• Damora Therapeutics, Inc. showed a decrease of -878.8% in Net Income Loss from 2024 to 2025.
• This data is from Damora Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Damora Therapeutics, Inc.'s Net Income Loss has declined by 474.8%.
• Historical annual values: Fiscal year 2025: -$209.84 million | Fiscal year 2024: -$21.44 million | Fiscal year 2023: -$38.35 million | Fiscal year 2022: -$61.62 million | Fiscal year 2021: -$51.75 million | Fiscal year 2020: -$34.84 million | Fiscal year 2019: -$36.51 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026